The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.
Participant has histologically or cytologically proven EC with recurrent or advanced disease.
Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.
Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;
Has first recurrent disease and is naïve to systemic anticancer therapy for EC;
Participant has a concomitant malignancy, or participant has a prior non-endometrial invasive malignancy who has been disease-free for <3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
Participant has any medical history of interstitial lung disease or pneumonitis.
Participant has cirrhosis or current unstable liver or biliary disease.
Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.